Genetic Analysis AS: Genetic Analysis publishes Simplified disclosure document relating to the previously announced subsequent offering
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW.
Today, June 2, 2025, Genetic Analysis AS ("GA" or the "Company") publishes a Simplified disclosure document relating to the Company's forthcoming subsequent offering with gross proceeds of up to approximately NOK 7.1 million and 8,230,545 new shares with preferential rights for existing shareholders (the "Subsequent Offering"). The subscription period begins on Thursday, June 5, 2025. The Exemption Document is available on the Company's and Sedermera Corporate Finance AB's respective websites (www.genetic-analysis.com, www.sedermera.se).
Publication of Simplified disclosure document
The Simplified disclosure document, including complete terms and conditions and instructions of subscription and payment, is available on the Company's and Sedermera Corporate Finance AB's respective websites (www.genetic-analysis.com, www.sedermera.se).
Indicative timetable for the Subsequent Offering
- Subscription period: June 5, 2025 to June 16, 2025 at 12:00 hours (CET).
- Trading in subscription rights: June 5, 2025 to June 12, 2025 at 16:30 hours
- Announcement of the final outcome of the Subsequent Offering: around June 18, 2025
Subscription rights
Shareholders in the Company as of June 2, 2025, as registered in the Company's shareholders' register with Euronext Securities Oslo on June 4, 2025 (the record date), will receive tradable subscription rights that, subject to any restrictions under applicable law, give preferential rights to subscribe for, and be allocated, offer shares in the Subsequent Offering in proportion to their shareholding in the Company on the record date. A total number of 49.383.271 tradeable subscription rights will be issued and six (6) subscription rights give the right to subscribe for one (1) new share at a subscription price of NOK 0,86 per share.
Share capital and number of shares
Genetic Analysis AS has today 49.383.271 shares outstanding and 14.890.576 shares under registration. The number of shares will, provided that the Subsequent offer is fully subscribed increase by 8.230.545 to a total of 72.504.392.
The Share capital will correspondingly increase from NOK 29.629.962,60 and with NOK 8.934.345,60 with the registration of the directed offering and further with NOK 4.938.927 to NOK 43.502.635,20 provided that the Subsequent offer is fully subscribed.
Special undertakings
The issue is not guaranteed or presubscribed by any party. Oversubscriptions are allowed and the principles for allocation in case of oversubscription can be found in the Simplified disclosure document.
Advisors
In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.